Alteration of saliva and blood ghrelin, obestatin, leptin and weight based on adjuvant chemotherapy treatment in early-stage operated breast cancer patients

Aim: To evaluate the weight change and ghrelin, obestatin and leptin levels in operated early stage breast cancer patients receivingadjuvant chemotherapy.Material and Methods: This study was conducted with 22 operated breast cancer patients (examined before and after adjuvantchemotherapy) and 33 BMI-matched two different healthy controls (of 33 healthy controls, 17 BMI-matched control was usedto compare before adjuvant chemotherapy, 16 BMI-matched control was used to compare after adjuvant chemotherapy). Age,anthropometric measurements (weight, BMI, waist circumference), and blood biochemistry were recorded. Blood and salivary totalghrelin, obestatin and leptin levels are measured by using ELISA.Results: The mean ± SD weight (67.2 ± 12.3 and 72.9 ± 11.8 kg., p

PDF

___

1. T. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:359-86.
2. Fujii T, Le Du F, Xiao L, et al. Effectiveness of an adjuvant chemotherapy regimen for early-stage breast cancer: a systematic review and network meta-analysis. JAMA Oncol 2015;1:1311-8.
3. Autier P, Boniol M, Gavin A, et al. Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. BMJ 2011;343:4411.
4. Villarini A, Pasanisi P, Raimondi M, et al. Preventing weight gain during adjuvant chemotherapy for breast cancer: a dietary intervention study. Breast Cancer Res Treat 2012;135:581-9.
5. Vance V, Mourtzakis M, McCargar L, et al. Weight gain in breast cancer survivors: prevalence, pattern and health consequences. Obes Rev 2011;12:282-94.
6. Demark-Wahnefried W, Peterson BL, Winer EP, et al. Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2001;19:2381-9.
7. Buch K, Gunmalm V, Andersson M, et al. Effect of chemotherapy and aromatase inhibitors in the adjuvant treatment of breast cancer on glucose and insulin metabolism-A systematic review Cancer Med 2019;8:238-45.
8. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature 2001;409:194-8.
9. Soriano-Guillen L, Barrios V, Campos-Barros A, et al. Ghrelin levels in obesity and anorexia nervosa: effect of weight reduction or recuperation. J Pediatr 2004;144:36-42.
10. Masuda Y, Tanaka T, Inomata N, et al. Ghrelin stimulates gastric acid secretion and motility in rats. Biochem Biophys Res Commun 2000;276:905-8.
11. Garcia JM, Garcia-Touza M, Hijazi RA, et al. Active ghrelin levels and active/total ghrelin ratio in cancerinduced cachexia. J Clin Endocrinol Metab 2005; 90:2920-6.
12. Zhang JV, Ren PG, Avsian-Kretchmer O, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin’s effects on food intake. Science 2005;310:996-9.
13. Lauwers E, Landuyt B, Arckens L, et al. Obestatin does not activate orphan G protein-coupled receptor GPR39. Biochem Biophys Res Commun 2006;351:21- 5.
14. Aydin S. Discovery of ghrelin hormone: re searches and clinical applications. Turk J Biochem 2007;32: 76-89.
15. Staiger H, Tschritter O, Machan J. Relationship of serum adiponectin and leptin concentrations with body fat distribution in humans. Obes Res 2003;11:368-72.
16. Konstantinides S, Schafer K, Koschinick S, et al. Leptindependent platelet aggregation and arterial thrombosis suggest a mechanism for atherothrombotic disease inobesity. J Clin Invest 2001;108: 1533-40.
17. Tessitore L, Vizio B, Pesola D, et al. Adipocyte expression and circulating levels of leptin increase in both gynaecological and breast cancer patients. Int J Oncol 2004; 24:1529-35.
18. Alacacioglu A, Kebapcilar L, Gokgoz Z, et al. Leptin, insulin and body composition changes during adjuvant taxane based chemotherapy in patients with breast cancer, preliminary study. Indian J Cancer 2016;53:39-42.
19. Mutschler NS, Scholz C, Friedl TWP, et al. Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study. Clin Breast Cancer 2018;18:175-83.
20. Basaran G, Turhal NS, Cabuk D, et al. Weight gain after adjuvant chemotherapy in patients with early breast cancer in Istanbul Turkey. Med Oncol 2011;28:409-15.
21. Atalay C, Kucuk A. The impact of weight gain during adjuvant chemotherapy on survival in breast cancer. Ulus Cerrahi Derg 2015;31:124-7.
22. Wolf I, Sadetzki S, Kanety H, et al. Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer 2006;106:966-73.
23. Korbonits M, Goldstone AP, Gueorguiev M, et al. Ghrelin - a hormone with multiple functions. Front in Neuroend 2004;25:27-68.
24. Peino R, Baldelli R, Rodriguez-Garcia J, et al. Ghrelin induced growth hormone secretion in humans. Eur J Endocrinol 2000;143:11-4.
25. Enomoto M, Nagaya N, Uematsu M, et al. Cardiovascular and hormonal effects of subcutaneus administration of ghrelin, annovel GHR-P in healty humans. Clin Sci 2003;10.
26. Kojima M, Hosoda H, Matsuo H, et al. Ghrelin; discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends in Endocrinology and Metabolism 2001;12:118-22.
27. Granata R, Settanni F, Biancone L, et al. Acylated and unacylated ghrelin promote proliferation and inhibit apoptosis of pancreatic cells and human islets. Involment of cAMP/PKA, ERK1/2 and PI3K/AKT signalling. Endocrinology 2007;148:512-29.
28. Hiura Y, Takiguchi S, Yamamoto K, et al. Fall in plasma ghrelin concentrations after cisplatin-based chemotherapy in esophageal cancer patients. Int J Clin Oncol 2012;17:316-23
29. Malik NM, Moore GB, Kaur R, et al. Adaptive up– regulation of gastric and hypothalamic ghrelin receptors and increased plasma ghrelin in a model of cancer chemotherapy-induced dyspepsia. Regul Pept 2008;148:33-8.
30. Liu YL, Malik NM, Sanger GJ, et al. Ghrelin alleviates cancer chemotherapy-associated dyspepsia in rodents. Cancer Chemother Pharmacol 2006;58:326- 33.
31. Riezzo G, Clemente C, Linsalata M, et al. Gut peptide profile and chemotherapy-associated dyspepsia syndrome in patients with breast cancer undergoing FEC60 chemotherapy. Anticancer Res 2013;33:4951- 7.
32. Mantzoros C. The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med 1999;130:671-80.
33. Montague CT, Farooqi IS, Whitehead JP, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997;387: 903-8.
34. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normalweight and obese humans. N Engl J Med 1996;334: 292-5.
35. Coskun T, Kosova F, Ari Z, et al. Effect of oncological treatment on serum adipocytokine levels in patients with stage II-III breast cancer. Mol Clin Oncol 2016;4:893-7.
36. 36. Dieli-Conwright CM, Wong L, Waliany S, et al. An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy. Cancer 2016;122:2646-53.
37. Beaumont NJ, Skinner VO, Tan TM, et al. Ghrelin can bind to a species of high density lipoprotein associated with paraoxonase. J Biol Chem 2003; 278:8877-80.
38. Aydin S. A comparison of ghrelin, glucose, alphaamylase and protein levels in saliva from diabetics. J Biochem Mol Biol 2007;40:29-35.
39. Demirkan B, Alacacioglu A, Yilmaz U. Relation of body mass index (BMI) to disease free (DFS) and distant disease free survivals (DDFS) among Turkish women with operable breast carcinoma. Jpn J Clin Oncol 2007;37:256-65.